
    
      This study is a mono-center, randomization, double-blind clinical trial in healthy subjects
      between 18 to 50. Under the premise of full informed consent, 360 subjects that meet the
      requirement of clinical trial in the age of 18-50 will be divided into 3 groups and injected
      3 consecutive batches of HecolinÂ® separately. The main outcome measures are the
      immunogenicity evaluation and safety surveillance after inoculation according to prescribed
      immunization procedure.
    
  